ClinicalTrials.gg
CompletedNCT02533375Updated Jan 14, 2019Results posted

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

A Phase 3 interventional study of Adalimumab in Generalized Pustular Psoriasis (GPP), Adalimumab and Japanese, sponsored by AbbVie. Completed. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
46th of 48
10 · median 148
Started
2015
with 2 others
Phase 3
26 of 48
1 open now
Registered
31st of 48
by date
Lead sponsor
3 of 48
AbbVie

Among the 48 studies testing adalimumab in Psoriasis, this one is the 46th largest by enrollment, is one of 3 that started in 2015, is one of 26 in phase 3, and was the 31st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently approved treatment.

Read the detailed description

This was a Phase 3, multicenter, open-label, single-arm study of adalimumab in Japanese participants with generalized pustular psoriasis (GPP). The study included a 30-day screening period, a 52-week treatment period, and a 70-day follow-up period. The dose regimen of adalimumab used in this study was 80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.

03

Conditions studied

  • Generalized Pustular Psoriasis (GPP)
  • Adalimumab
  • Japanese

Browse trials for

Keywords

  • efficacy
  • safety
04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of generalized pustular psoriasis
  • Total skin score of at least 3 and erythema with pustules (skin score of at least 1) at baseline in the Japan Dermatology Association (JDA) severity index of Generalized Pustular Psoriasis (GPP) in GPP Medical Care Guideline 2014 in Japan
  • Inadequate response to, or intolerance to, or to the currently approved GPP treatment (excluding infliximab)
  • Infliximab secondary failure, or intolerant to infliximab

Exclusion criteria

Exclusion Criteria:

  • Erythrodermic psoriasis, guttate psoriasis or sub-corneal pustular dermatosis at Screening
  • Drug-induced GPP
  • Cannot stop ongoing use of prohibited GPP treatments
  • Total JDA severity index of GPP of 14 or more in GPP Medical Care Guideline 2014 in Japan
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Participants receiving adalimumab

    80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.

    Drug: Adalimumab

Interventions

  • Adalimumab pre-filled syringe, administered by subcutaneous injection

    Also known as: Humira, ABT-D2E7

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Clinical Response at Week 16

    Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) relative to baseline (Day 1), according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical Response was defined as the improvement (reduction) of total skin score of at least 1 point (if the participant's baseline total skin score was 3); improvement (reduction) at least 2 points (if the participant's baseline total skin score was 4-9); or remission if the total skin score was 0.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Number of Participants Achieving Clinical Response Over Time

    Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) relative to baseline (Day 1), according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical Response was defined as the improvement (reduction) of total skin score of at least 1 point (if the participant's baseline total skin score was 3); improvement (reduction) at least 2 points (if the participant's baseline total skin score was 4-9); or remission if the total skin score was 0.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52

  2. Number of Participants Achieving Clinical Remission Over Time

    The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical remission was defined as a total skin score of 0.

    Time frame: Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  3. Mean Change From Baseline in the Total GPP Score Over Time

    The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  4. Mean Change From Baseline in JDA Severity Index of GPP Over Time

    The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). A total score on the JDA severity index of 0-6 is categorized as "Mild", "Moderate" is 7-10, and "Severe" is 11-17.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  5. Mean Change From Baseline in Total Skin Score Over Time

    The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  6. Mean Percent Change From Baseline in Total Skin Score Over Time

    The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  7. Mean Change From Baseline in Total Systemic/Laboratory Test Score Over Time

    The Generalized Pustular Psoriasis (GPP) total systemic/laboratory test score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  8. Mean Change From Baseline in Total Erythema Area Over Time

    The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of erythema (redness) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total erythema area is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 75%; moderate, ≥ 25% and \< 75%; mild, \< 25%); and none (0%). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  9. Mean Change From Baseline in Total Erythema Area With Pustules Over Time

    The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of erythema with pustules (small pockets of pus) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total erythema area with pustules is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 50%; moderate, ≥ 10% and \< 50%; mild, \< 10%); and none (0%). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  10. Mean Change From Baseline in Total Edema Area Over Time

    The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of edema (swelling) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total area of edema is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 50%; moderate, ≥ 10% and \< 50%; mild, \< 10%); and none (0%). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  11. Mean Change From Baseline in Body Temperature Over Time

    Body temperature (oral) was obtained at each visit prior to blood sampling.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  12. Mean Change From Baseline in White Blood Cell (WBC) Concentration Over Time

    Blood was drawn at each study visit, and white blood cell concentration was determined.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  13. Mean Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Over Time

    Blood was drawn at each study visit, and high-sensitivity C-reactive protein (hs-CRP) concentration was determined.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  14. Mean Change From Baseline in Serum Albumin Over Time

    Blood was drawn at each study visit, and serum albumin concentration was determined.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  15. Number of Participants Achieving "Mild" in the JDA Severity Index of Generalized Pustular Psoriasis (GPP) for Participants With "Moderate" or "Severe" at Baseline Over Time

    The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). A total score on the JDA severity index of 0-6 is categorized as "Mild", "Moderate" is 7-10, and "Severe" is 11-17.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  16. Proportion of Participants Achieving Treatment Success in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Over Time

    The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number. Treatment Success was defined by at least a 2 grade improvement relative to baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  17. Change From Baseline in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade Over Time

    The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  18. Proportion of Participants Achieving Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade 0 or 1 for Those With PGA Grade of at Least 2 at Baseline Over Time

    The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  19. Proportion of Participants Achieving Psoriasis Area and Severity Index 90 (PASI 90) Over Time

    The proportion of participants with a ≥ 90% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  20. Proportion of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Over Time

    The proportion of participants with a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  21. Proportion of Participants Achieving Psoriasis Area and Severity Index 50 (PASI 50) Over Time

    The proportion of participants with a ≥ 50% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  22. Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time

    The mean change in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  23. Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time

    The percent change in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52

  24. Proportion of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 Over Time

    The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment- related feelings. Participants respond to 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means that psoriasis has an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all.

    Time frame: Week 8, Week 16, Week 24, Week 36, Week 52

  25. Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time

    The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment- related feelings. Participants respond to 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means that psoriasis has an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 8, Week 16, Week 24, Week 36, Week 52

  26. Mean Change From Baseline in Short Form-36 Health Status Survey Version 2 (SF-36 V2) Score Over Time

    The Short Form-36 Health Status Survey Version 2 (SF-36 V2) is a 36-item generic health-related quality of life questionnaire to assess the participant's view of their health consisting of 2 components: physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.

    Time frame: Baseline, Week 8, Week 16, Week 24, Week 36, Week 52

  27. Proportion of Participants Taking Systemic Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study

    GPP-specific co-medications were documented at each scheduled study visit.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52

  28. Proportion of Participants Taking Topical Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study

    Participants using topical co-medications for GPP were documented at each scheduled study visit.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52

07

Results

Posted Jan 14, 2019

Participant flow

Participant flow — Overall Study
MilestoneParticipants Receiving Adalimumab
Started10
Completed5
Not completed5
Withdrew: Lack of efficacy3
Withdrew: Adverse event2

Outcome measures

PrimaryProportion of Participants Achieving Clinical Response at Week 16

Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) relative to baseline (Day 1), according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical Response was defined as the improvement (reduction) of total skin score of at least 1 point (if the participant's baseline total skin score was 3); improvement (reduction) at least 2 points (if the participant's baseline total skin score was 4-9); or remission if the total skin score was 0.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Clinical Response at Week 16
ParticipantsParticipants Receiving Adalimumab
Proportion of Participants Achieving Clinical Response at Week 167
SecondaryNumber of Participants Achieving Clinical Response Over Time

Clinical Response was defined as reduction of the Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) relative to baseline (Day 1), according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical Response was defined as the improvement (reduction) of total skin score of at least 1 point (if the participant's baseline total skin score was 3); improvement (reduction) at least 2 points (if the participant's baseline total skin score was 4-9); or remission if the total skin score was 0.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52
Reported as:
Number · participants
Number of Participants Achieving Clinical Response Over Time
participantsParticipants Receiving Adalimumab
Week 25
Week 46
Week 86
Week 125
Week 246
Week 366
Week 525
SecondaryNumber of Participants Achieving Clinical Remission Over Time

The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Clinical remission was defined as a total skin score of 0.

Time frame:
Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Number · participants
Number of Participants Achieving Clinical Remission Over Time
participantsParticipants Receiving Adalimumab
Week 20
Week 41
Week 80
Week 120
Week 160
Week 240
Week 360
Week 520
SecondaryMean Change From Baseline in the Total GPP Score Over Time

The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in the Total GPP Score Over Time
units on a scaleParticipants Receiving Adalimumab
Week 2-2.9 ± 2.08
Week 4-3.8 ± 2.15
Week 8-3.2 ± 2.57
Week 12-3.1 ± 2.85
Week 16-4.6 ± 1.85
Week 24-3.8 ± 3.15
Week 36-5.5 ± 2.07
Week 52-6.0 ± 2.55
SecondaryMean Change From Baseline in JDA Severity Index of GPP Over Time

The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). A total score on the JDA severity index of 0-6 is categorized as "Mild", "Moderate" is 7-10, and "Severe" is 11-17.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Mean Change From Baseline in JDA Severity Index of GPP Over Time
ParticipantsParticipants Receiving Adalimumab
Baseline — Mild3
Baseline — Moderate6
Baseline — Severe1
Baseline — Missing0
Week 2 — Mild7
Week 2 — Moderate3
Week 2 — Severe0
Week 2 — Missing0
Week 4 — Mild9
Week 4 — Moderate1
Week 4 — Severe0
Week 4 — Missing0
Week 8 — Mild8
Week 8 — Moderate1
Week 8 — Severe1
Week 8 — Missing0
Week 12 — Mild7
Week 12 — Moderate0
Week 12 — Severe1
Week 12 — Missing2
Week 16 — Mild7
Week 16 — Moderate1
Week 16 — Severe0
Week 16 — Missing2
Week 24 — Mild7
Week 24 — Moderate0
Week 24 — Severe1
Week 24 — Missing2
Week 36 — Mild6
Week 36 — Moderate0
Week 36 — Severe0
Week 36 — Missing4
Week 52 — Mild5
Week 52 — Moderate0
Week 52 — Severe0
Week 52 — Missing5
SecondaryMean Change From Baseline in Total Skin Score Over Time

The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in Total Skin Score Over Time
units on a scaleParticipants Receiving Adalimumab
Week 2-1.9 ± 1.66
Week 4-2.4 ± 1.65
Week 8-2.3 ± 1.49
Week 12-2.3 ± 1.98
Week 16-3.1 ± 1.36
Week 24-2.6 ± 1.92
Week 36-3.8 ± 1.47
Week 52-4.2 ± 1.79
SecondaryMean Percent Change From Baseline in Total Skin Score Over Time

The Generalized Pustular Psoriasis (GPP) total skin score (range 0-9, with 9 representing severe symptoms) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · percentage change from baseline
Mean Percent Change From Baseline in Total Skin Score Over Time
percentage change from baselineParticipants Receiving Adalimumab
Week 2-33.8 ± 27.71
Week 4-43.4 ± 27.28
Week 8-42.9 ± 27.12
Week 12-39.9 ± 30.36
Week 16-54.6 ± 20.77
Week 24-46.6 ± 33.15
Week 36-67.9 ± 13.58
Week 52-72.3 ± 16.34
SecondaryMean Change From Baseline in Total Systemic/Laboratory Test Score Over Time

The Generalized Pustular Psoriasis (GPP) total systemic/laboratory test score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in Total Systemic/Laboratory Test Score Over Time
units on a scaleParticipants Receiving Adalimumab
Week 2-1.0 ± 1.05
Week 4-1.4 ± 0.97
Week 8-0.9 ± 1.45
Week 12-0.9 ± 1.25
Week 16-1.5 ± 1.20
Week 24-1.1 ± 1.64
Week 36-1.7 ± 1.21
Week 52-1.8 ± 1.30
SecondaryMean Change From Baseline in Total Erythema Area Over Time

The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of erythema (redness) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total erythema area is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 75%; moderate, ≥ 25% and \< 75%; mild, \< 25%); and none (0%). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in Total Erythema Area Over Time
units on a scaleParticipants Receiving Adalimumab
Week 2-17.0 ± 20.08
Week 4-21.6 ± 22.81
Week 8-19.7 ± 26.62
Week 12-23.0 ± 26.28
Week 16-34.6 ± 27.30
Week 24-27.6 ± 29.48
Week 36-48.3 ± 27.72
Week 52-44.6 ± 37.50
SecondaryMean Change From Baseline in Total Erythema Area With Pustules Over Time

The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of erythema with pustules (small pockets of pus) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total erythema area with pustules is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 50%; moderate, ≥ 10% and \< 50%; mild, \< 10%); and none (0%). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in Total Erythema Area With Pustules Over Time
units on a scaleParticipants Receiving Adalimumab
Week 2-9.3 ± 8.96
Week 4-11.7 ± 9.01
Week 8-8.3 ± 11.42
Week 12-8.3 ± 14.63
Week 16-11.8 ± 10.65
Week 24-7.1 ± 16.75
Week 36-13.3 ± 12.44
Week 52-14.8 ± 13.31
SecondaryMean Change From Baseline in Total Edema Area Over Time

The Generalized Pustular Psoriasis (GPP) skin score scores for the total area of edema (swelling) were calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total area of edema is evaluated on a scale of 0 (none) to 3 (severe), with the percentage of body surface area involvement defined as follows: severe ≥ 50%; moderate, ≥ 10% and \< 50%; mild, \< 10%); and none (0%). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in Total Edema Area Over Time
units on a scaleParticipants Receiving Adalimumab
Week 2-9.1 ± 9.45
Week 4-12.8 ± 11.29
Week 8-12.4 ± 17.30
Week 12-6.3 ± 31.96
Week 16-15.4 ± 17.30
Week 24-14.0 ± 17.72
Week 36-21.2 ± 14.68
Week 52-18.6 ± 14.31
SecondaryMean Change From Baseline in Body Temperature Over Time

Body temperature (oral) was obtained at each visit prior to blood sampling.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · degrees Celsius
Mean Change From Baseline in Body Temperature Over Time
degrees CelsiusParticipants Receiving Adalimumab
Week 2-0.3 ± 0.68
Week 4-0.5 ± 0.52
Week 8-0.3 ± 0.50
Week 12-0.1 ± 0.64
Week 16-0.3 ± 0.50
Week 24-0.5 ± 1.04
Week 36-0.3 ± 0.86
Week 52-0.1 ± 0.64
SecondaryMean Change From Baseline in White Blood Cell (WBC) Concentration Over Time

Blood was drawn at each study visit, and white blood cell concentration was determined.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · cells/µL
Mean Change From Baseline in White Blood Cell (WBC) Concentration Over Time
cells/µLParticipants Receiving Adalimumab
Week 2-1220.0 ± 1970.22
Week 4-1770.0 ± 2572.96
Week 8-810.0 ± 3104.28
Week 12-1650.0 ± 2857.57
Week 16-2562.5 ± 2960.18
Week 24-1162.5 ± 4444.88
Week 36-2550.0 ± 3229.09
Week 52-2760.0 ± 2966.99
SecondaryMean Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Over Time

Blood was drawn at each study visit, and high-sensitivity C-reactive protein (hs-CRP) concentration was determined.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · mg/dL
Mean Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Over Time
mg/dLParticipants Receiving Adalimumab
Week 2-1.5 ± 4.12
Week 4-1.6 ± 4.05
Week 8-0.3 ± 5.97
Week 12-1.7 ± 4.76
Week 16-2.5 ± 4.06
Week 24-1.5 ± 5.63
Week 36-2.7 ± 5.02
Week 52-3.8 ± 4.73
SecondaryMean Change From Baseline in Serum Albumin Over Time

Blood was drawn at each study visit, and serum albumin concentration was determined.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · g/dL
Mean Change From Baseline in Serum Albumin Over Time
g/dLParticipants Receiving Adalimumab
Week 20.0 ± 0.33
Week 40.1 ± 0.44
Week 80.1 ± 0.38
Week 12-0.2 ± 0.59
Week 16-0.0 ± 0.39
Week 24-0.0 ± 0.26
Week 36-0.1 ± 0.54
Week 52-0.0 ± 0.43
SecondaryNumber of Participants Achieving "Mild" in the JDA Severity Index of Generalized Pustular Psoriasis (GPP) for Participants With "Moderate" or "Severe" at Baseline Over Time

The Generalized Pustular Psoriasis (GPP) total score (range 0-17, with 17 representing severe disease) was calculated according to Japan Dermatology Association (JDA) severity index in GPP medical care guideline 2014. The total skin score (range 0-9, with 9 representing severe symptoms) is the combined skin scores for area of erythema (redness), area of erythema with pustules (small pockets of pus), and area of edema (swelling). The systemic and laboratory results score (\[range 0-8, with 8 representing severe disease\] assesses body temperature, white blood cell \[WBC\] count, high-sensitivity C-reactive protein \[hs-CRP\], and serum albumin). A total score on the JDA severity index of 0-6 is categorized as "Mild", "Moderate" is 7-10, and "Severe" is 11-17.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Number of Participants Achieving "Mild" in the JDA Severity Index of Generalized Pustular Psoriasis (GPP) for Participants With "Moderate" or "Severe" at Baseline Over Time
ParticipantsParticipants Receiving Adalimumab
Week 24
Week 46
Week 85
Week 125
Week 165
Week 245
Week 365
Week 524
SecondaryProportion of Participants Achieving Treatment Success in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Over Time

The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number. Treatment Success was defined by at least a 2 grade improvement relative to baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Treatment Success in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Over Time
ParticipantsParticipants Receiving Adalimumab
Week 23
Week 45
Week 84
Week 123
Week 165
Week 244
Week 365
Week 523
SecondaryChange From Baseline in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade Over Time

The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Change From Baseline in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade Over Time
ParticipantsParticipants Receiving Adalimumab
Baseline — PGA Grade 00
Baseline — PGA Grade 10
Baseline — PGA Grade 24
Baseline — PGA Grade 33
Baseline — PGA Grade 43
Baseline — PGA Grade 50
Week 2 — PGA Grade 01
Week 2 — PGA Grade 13
Week 2 — PGA Grade 25
Week 2 — PGA Grade 31
Week 2 — PGA Grade 40
Week 2 — PGA Grade 50
Week 4 — PGA Grade 01
Week 4 — PGA Grade 17
Week 4 — PGA Grade 21
Week 4 — PGA Grade 31
Week 4 — PGA Grade 40
Week 4 — PGA Grade 50
Week 8 — PGA Grade 00
Week 8 — PGA Grade 18
Week 8 — PGA Grade 20
Week 8 — PGA Grade 31
Week 8 — PGA Grade 41
Week 8 — PGA Grade 50
Week 12 — PGA Grade 01
Week 12 — PGA Grade 14
Week 12 — PGA Grade 22
Week 12 — PGA Grade 30
Week 12 — PGA Grade 40
Week 12 — PGA Grade 51
Week 16 — PGA Grade 02
Week 16 — PGA Grade 15
Week 16 — PGA Grade 21
Week 16 — PGA Grade 30
Week 16 — PGA Grade 40
Week 16 — PGA Grade 50
Week 24 — PGA Grade 01
Week 24 — PGA Grade 15
Week 24 — PGA Grade 20
Week 24 — PGA Grade 32
Week 24 — PGA Grade 40
Week 24 — PGA Grade 50
Week 36 — PGA Grade 02
Week 36 — PGA Grade 14
Week 36 — PGA Grade 20
Week 36 — PGA Grade 30
Week 36 — PGA Grade 40
Week 36 — PGA Grade 50
Week 52 — PGA Grade 03
Week 52 — PGA Grade 12
Week 52 — PGA Grade 20
Week 52 — PGA Grade 30
Week 52 — PGA Grade 40
Week 52 — PGA Grade 50
SecondaryProportion of Participants Achieving Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade 0 or 1 for Those With PGA Grade of at Least 2 at Baseline Over Time

The Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall severity was evaluated using the following categories: erythema, pustulation, and edema, and graded as follows. Grade 0 = cleared, except for residual discoloration; Grade 1 = minimal; Grade 2 = mild; Grade 3 = moderate; Grade 4 = severe; and Grade 5 = very severe. The score is an arithmetic average of the grades for erythema, pustulation, and edema, rounded to the nearest whole number.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade 0 or 1 for Those With PGA Grade of at Least 2 at Baseline Over Time
ParticipantsParticipants Receiving Adalimumab
Week 24
Week 48
Week 88
Week 125
Week 167
Week 246
Week 366
Week 525
SecondaryProportion of Participants Achieving Psoriasis Area and Severity Index 90 (PASI 90) Over Time

The proportion of participants with a ≥ 90% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Psoriasis Area and Severity Index 90 (PASI 90) Over Time
ParticipantsParticipants Receiving Adalimumab
Week 21
Week 42
Week 81
Week 121
Week 160
Week 241
Week 363
Week 523
SecondaryProportion of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Over Time

The proportion of participants with a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Over Time
ParticipantsParticipants Receiving Adalimumab
Week 22
Week 42
Week 82
Week 122
Week 164
Week 244
Week 365
Week 523
SecondaryProportion of Participants Achieving Psoriasis Area and Severity Index 50 (PASI 50) Over Time

The proportion of participants with a ≥ 50% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Psoriasis Area and Severity Index 50 (PASI 50) Over Time
ParticipantsParticipants Receiving Adalimumab
Week 24
Week 46
Week 86
Week 125
Week 165
Week 244
Week 365
Week 524
SecondaryMean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time

The mean change in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time
units on a scaleParticipants Receiving Adalimumab
Week 2-12.9 ± 12.83
Week 4-17.4 ± 14.66
Week 8-14.9 ± 17.55
Week 12-14.3 ± 20.03
Week 16-19.1 ± 17.27
Week 24-16.8 ± 19.61
Week 36-28.1 ± 17.67
Week 52-26.7 ± 22.24
SecondaryMean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time

The percent change in the Psoriasis Area and Severity Index (PASI) score from baseline was calculated. PASI is a combination of the intensity of psoriasis, assessed for erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · percentage change from baseline
Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time
percentage change from baselineParticipants Receiving Adalimumab
Week 2-44.2 ± 27.47
Week 4-59.7 ± 24.65
Week 8-43.9 ± 45.01
Week 12-45.0 ± 39.20
Week 16-55.5 ± 31.89
Week 24-43.6 ± 46.26
Week 36-79.0 ± 24.13
Week 52-33.7 ± 117.4
SecondaryProportion of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 Over Time

The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment- related feelings. Participants respond to 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means that psoriasis has an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all.

Time frame:
Week 8, Week 16, Week 24, Week 36, Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 Over Time
ParticipantsParticipants Receiving Adalimumab
Week 81
Week 160
Week 241
Week 360
Week 522
SecondaryMean Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time

The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment- related feelings. Participants respond to 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means that psoriasis has an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 8, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time
units on a scaleParticipants Receiving Adalimumab
Week 8-4.2 ± 6.55
Week 16-6.6 ± 5.34
Week 24-4.8 ± 7.59
Week 36-6.5 ± 5.65
Week 52-8.0 ± 7.18
SecondaryMean Change From Baseline in Short Form-36 Health Status Survey Version 2 (SF-36 V2) Score Over Time

The Short Form-36 Health Status Survey Version 2 (SF-36 V2) is a 36-item generic health-related quality of life questionnaire to assess the participant's view of their health consisting of 2 components: physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.

Time frame:
Baseline, Week 8, Week 16, Week 24, Week 36, Week 52
Reported as:
Mean · units on a scale
Mean Change From Baseline in Short Form-36 Health Status Survey Version 2 (SF-36 V2) Score Over Time
units on a scaleParticipants Receiving Adalimumab
Physical Component Summary- Week 84.7 ± 19.05
Physical Component Summary- Week 169.2 ± 17.48
Physical Component Summary- Week 248.2 ± 15.94
Physical Component Summary- Week 364.9 ± 23.39
Physical Component Summary- Week 5212.0 ± 21.42
Mental Component Summary- Week 80.6 ± 8.71
Mental Component Summary- Week 160.9 ± 8.03
Mental Component Summary- Week 242.0 ± 8.32
Mental Component Summary- Week 361.6 ± 18.26
Mental Component Summary- Week 526.4 ± 7.79
SecondaryProportion of Participants Taking Systemic Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study

GPP-specific co-medications were documented at each scheduled study visit.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Taking Systemic Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study
ParticipantsParticipants Receiving Adalimumab
Etretinate3
Methotrexate2
Oral steroids1
Cyclosporine2
SecondaryProportion of Participants Taking Topical Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study

Participants using topical co-medications for GPP were documented at each scheduled study visit.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52
Reported as:
Count of participants · Participants
Proportion of Participants Taking Topical Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study
ParticipantsParticipants Receiving Adalimumab
Corticosteroid7
Vitamin D30
Tacrolimus0

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 70 days after the last dose of study drug (up to 62 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Receiving Adalimumab0/10 (0%)3/10 (30%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventParticipants Receiving Adalimumab
Cardiac failureCardiac disorders1/10
Chronic sinusitisInfections and infestations1/10
Enterocolitis bacterialInfections and infestations1/10
DehydrationMetabolism and nutrition disorders1/10
Renal failureRenal and urinary disorders1/10
Pustular psoriasisSkin and subcutaneous tissue disorders1/10
Most frequent other events
Showing 10 of 43
Most frequent other events
EventParticipants Receiving Adalimumab
NasopharyngitisInfections and infestations3/10
PruritusSkin and subcutaneous tissue disorders3/10
HypoalbuminaemiaMetabolism and nutrition disorders2/10
EosinophiliaBlood and lymphatic system disorders1/10
Cardiac failureCardiac disorders1/10
Autoimmune ThyroiditisEndocrine disorders1/10
Dry eyeEye disorders1/10
EpiscleritisEye disorders1/10
GlaucomaEye disorders1/10
Abdominal painGastrointestinal disorders1/10

Baseline characteristics

Full Analysis Set (FAS): all participants who received at least 1 dose of study drug and had at least 1 post-treatment efficacy assessment.

Age, Continuous
Age, Continuous(years)Participants Receiving Adalimumab
Mean49.8 ± 13.26
Sex: Female, Male
Sex: Female, Male(Participants)Participants Receiving Adalimumab
Female3
Male7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants Receiving Adalimumab
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Generalized Pustular Psoriasis (GPP) Duration
Generalized Pustular Psoriasis (GPP) Duration(years)Participants Receiving Adalimumab
Mean10.6 ± 12.59
Prior GPP Therapy
Prior GPP Therapy(Participants)Participants Receiving Adalimumab
Psoralen and ultraviolet A light (PUVA)1
Narrow-band ultraviolet B light (UVB)2
Granulocyte and Monocyte Absorbent Apheresis (GMA)2
None of the above5
Prior Infliximab Use
Prior Infliximab Use(Participants)Participants Receiving Adalimumab
Yes3
No7
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Sep 2016 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2015
First posted
Aug 26, 2015
Start
Sep 28, 2015
Primary completionActual
Sep 15, 2016
CompletionActual
Jul 20, 2017
Results first posted
Jan 14, 2019
Last update
Jan 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02533375
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 26, 2015
Start date
Sep 28, 2015
Primary completion
Sep 15, 2016
Completion
Jul 20, 2017
Results posted
Jan 14, 2019
Last update
Jan 14, 2019

Study contacts

Anne Robinson, PharmD
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion